Literature DB >> 1998954

Activated ras alleles in human carcinoma of the prostate are rare.

P H Gumerlock1, U R Poonamallee, F J Meyers, R W deVere White.   

Abstract

Although oncogenically activated ras alleles are common in some types of human cancers, the frequency in human carcinoma of the prostate (CaP) has not previously been addressed. In this paper, we report a comprehensive screening of 19 CaPs and 3 CaP cell lines for activating point mutations in the sequences of the 12th and 61st codons of c-Ha-ras-1 and the c-Ki-ras-2 genes, as well as the 12th, 13th, and 61st codons of the c-N-ras gene. The 19 CaPs were chosen to represent a wide range of stages (B through D), Gleason scores (3 through 10), and DNA ploidy (diploid with low proliferation to nontetraploid-aneuploid). Fifteen of the tumors had been untreated prior to resection and 4 were obtained postradiation therapy. The polymerase chain reaction was used to amplify genomic DNA sequences and transcribed mRNA sequences of the ras genes prior to allele-specific oligonucleotide probe hybridization. We have detected a mutant allele with a point mutation in the second nucleotide of the 61st codon of the c-Ha-ras-1 gene in one specimen. Thus, we conclude that the activation of ras alleles is not significant in the development or progression of most CaPs.

Entities:  

Mesh:

Year:  1991        PMID: 1998954

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Authors:  Hui Gao; Xuesong Ouyang; Whitney A Banach-Petrosky; William L Gerald; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

2.  RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.

Authors:  Dazhi Yang; Noemi Kedei; Luowei Li; Juan Tao; Julia F Velasquez; Aleksandra M Michalowski; Balázs I Tóth; Rita Marincsák; Attila Varga; Tamás Bíró; Stuart H Yuspa; Peter M Blumberg
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

Review 4.  Molecular and cellular markers for metastatic prostate cancer.

Authors:  C W Rinker-Schaeffer; W B Isaacs; J T Isaacs
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

5.  Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines.

Authors:  F K Asadi; R Sharifi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

6.  Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras.

Authors:  J S Rhim; M M Webber; D Bello; M S Lee; P Arnstein; L S Chen; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

Review 7.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 8.  Signaling inhibitors in the treatment of prostate cancer.

Authors:  Gary R Hudes
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

9.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 10.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.